Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations

被引：0

作者：

Millot, Frederic ^{[1
]}

Ampatzidou, Mirella ^{[2
]}

Moulik, Nirmalya Roy ^{[3
]}

Tewari, Sanjay ^{[4
]}

Elhaddad, Alaa ^{[5
]}

Hammad, Mahmoud ^{[5
]}

Pichler, Herbert ^{[6
]}

Lion, Thomas ^{[7
,8
]}

Tragiannidis, Athanasios ^{[9
]}

Shima, Haruko ^{[10
]}

An, Wenbin ^{[11
]}

Yang, Wenyu ^{[11
]}

Karow, Axel ^{[12
]}

Farah, Roula ^{[13
]}

Luesink, Maaike ^{[14
]}

Dworzak, Michael ^{[6
,7
]}

Sembill, Stephanie ^{[12
]}

De Moerloose, Barbara ^{[15
]}

Sedlacek, Petr ^{[16
]}

Schultz, Kirk R. ^{[17
]}

Kalwak, Krzysztof ^{[18
]}

Versluys, Birgitta ^{[19
]}

Athale, Uma ^{[20
]}

Hijiya, Nobuko ^{[21
]}

Metzler, Markus ^{[12
]}

Suttorp, Meinolf ^{[22
]}

机构：

[1] Univ Hosp Poitiers, Inserm CIC 1402, Poitiers, France

[2] Aghia Sophia Childrens Hosp, Dept Pediat Hematol Oncol TAO, Athens, Greece

[3] Tata Mem Hosp, Homi Bhabha Natl Inst, Dept Pediat Oncol, Mumbai, India

[4] Royal Marsden NHS Fdn Trust Sutton, Dept Paediat Oncol Haematol, Sutton, England

[5] Cairo Univ, Childrens Canc Hosp, NCI, Dept Pediat Oncol, Cairo, Egypt

[6] Med Univ Vienna, St Anna Childrens Hosp, Dept Pediat & Adolescent Med, Vienna, Austria

[7] St Anna Childrens Canc Res Inst CCRI, Vienna, Austria

[8] Labdia Labordiagnost, Vienna, Austria

[9] Aristotle Univ Thessaloniki, AHEPA Univ Hosp, Sch Med, Dept Pediat 2,Fac Hlth Sci, Thessaloniki, Greece

[10] Keio Univ, Sch Med, Dept Pediat, Tokyo, Japan

[11] CAMS & PUMC, Inst Hematol & Blood Dis Hosp, Natl Clin Res Ctr Blood Dis, State Key Lab Expt Hematol,Haihe Lab Cell Ecosyst, Tianjin, Peoples R China

[12] Univ Hosp, Dept Pediat & Adolescent Med, Div Pediat Oncol & Hematol, Erlangen, Germany

[13] Lebanese Amer Univ, Med Ctr, Rizk Hosp, Dept Pediat, Beirut, Lebanon

[14] Princess Maxima Ctr Pediat Oncol, Dept Hemato Oncol, Utrecht, Netherlands

[15] Ghent Univ Hosp, Dept Pediat Hematol Oncol & Stem Cell Transplantat, Ghent, Belgium

[16] Charles Univ Prague, Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic

[17] British Columbia Childrens Hosp, BMT, Div Hematol Oncol, Vancouver, BC, Canada

[18] Wroclaw Med Univ, Dept Pediat Hematol Oncol & BMT, Wroclaw, Poland

[19] Princess Maxima Ctr, Dept Pediat Blood & Marrow Transplantat, Utrecht, Netherlands

[20] McMaster Univ, Dept Pediat, Div Haematol Oncol, Hamilton, ON, Canada

[21] Columbia Univ, Irving Med Ctr, Dept Pediat, New York, NY 10069 USA

[22] Tech Univ, Med Fac, Dept Pediat Hematol & Oncol, Dresden, Germany

来源：

LEUKEMIA | 2025年

关键词：

CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE INHIBITORS; STEM-CELL TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; LONG-TERM SURVIVAL; DOSE IMATINIB; PROGNOSTIC DISCRIMINATION; CYTOGENETIC RESPONSE; MOLECULAR RESPONSES; CML;

D O I：

10.1038/s41375-025-02543-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The treatment strategy for children and adolescents with chronic myeloid leukemia in the chronic phase (CML-CP) has evolved from allogeneic hematopoietic stem cell transplantation (HSCT) to tyrosine kinase inhibitors (TKIs). With the advent of next-generation TKIs and new targeted therapies in the CML field, an international pediatric CML expert panel provides recommendations based on the medical literature (including previous pediatric guidelines), national standards, and treatment principles used in adults with CML-CP. Recommendations include diagnosis of the disease and details on managing the initial steps of care of children and adolescents with newly diagnosed CML-CP, including complications such as leukostasis. The treatment recommendations are based on the initiation of therapy with a first- or second-generation TKI according to the allocated European Treatment and Outcome Study (EUTOS) long-term survival score risk group of the patient. The subsequent steps are based on the results of recommended monitoring which can justify a switch to another TKI or a drug in development if there is resistance or toxicity. The panel also provides recommendations regarding the discontinuation criteria for TKIs in children and adolescents in sustained deep molecular response. Allogeneic HSCT is not recommended as the first-line of treatment for children with CML-CP but is to be considered in case of progression to the advanced phase or failure of several lines of treatment. The present treatment and management recommendations are intended to provide advice to clinicians in view of optimizing the care and the outcome of children and adolescents with CML-CP.

引用

页码：779 / 791

页数：13

共 108 条

[1] Millot F., Suttorp M., Chronic myeloid Leukemia in children, Haematolymphoid disorders—WHO classification book on paediatric tumours, pp. 4-7, (2023)
[2] Suttorp M., Millot F., Sembill S., Deutsch H., Metzler M., Definition, epidemiology, pathophysiology, and essential criteria for diagnosis of pediatric chronic myeloid leukemia, Cancers, 13, (2021)
[3] Ford M., Mauro M., Aftandilian C., Sakamoto K.M., Hijiya N., Management of chronic myeloid leukemia in children and young adults, Curr Hematol Malig Rep, 17, pp. 121-126, (2022)
[4] de la Fuente J., Baruchel A., Biondi A., de Bont E., Dresse M.F., Suttorp M., Et al., Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years, Br J Haematol, 167, pp. 33-47, (2014)
[5] Athale U., Hijiya N., Patterson B.C., Bergsagel J., Andolina J.R., Bittencourt H., Et al., Management of chronic myeloid leukemia in children and adolescents: recommendations from the Children’s Oncology Group CML Working Group, Pediatr Blood Cancer, 66, (2019)
[6] Hijiya N., Schultz K.R., Metzler M., Millot F., Suttorp M., Pediatric chronic myeloid leukemia is a unique disease that requires a different approach, Blood, 127, pp. 392-399, (2016)
[7] Sembill S., Ampatzidou M., Chaudhury S., Dworzak M., Kalwak K., Karow A., Et al., Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations, Leukemia, 37, pp. 505-517, (2023)
[8] Hijiya N., Maschan A., Rizzari C., Shimada H., Dufour C., Goto H., Et al., Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia, Blood, 134, pp. 2036-2045, (2019)
[9] Brivio E., Pennesi E., Willemse M.E., Huitema A.D.R., Jiang Y., van Tinteren H.D.R., Et al., Bosutinib in resistant and intolerant pediatric patients with chronic phase chronic myeloid leukemia: results from the phase I part of study ITCC054/COG AAML1921, J Clin Oncol, 42, pp. 821-831, (2023)
[10] Millot F., De Keizer J., Metzler M., Suttorp M., Sedlacek P., Luesink M., Et al., Is the Eutos Long Term Survival (ELTS) score a useful marker to predict outcome in children with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP)? The experience of the International Registry of Childhood CML

← 1 2 3 4 5 6 7 8 9 10 →